Should MRD negative status be the end point of myeloma therapy?

With the development of technologies that can measure presence of a single myeloma cell in 1 million blood or marrow cells and emerging data showing that attaining minimal residual disease (MRD)–negative status predicts for significant improvement in survival, the critical question is whether we are now ready to utilize MRD-negative status as a standard end point in all of our clinical studies as well as incorporate it into our regular clinical practice. In this Point-Counterpoint, Kenneth Anderson and Pieter Sonneveld discuss whether MRD negativity should or should not become a standard of care in myeloma therapy.

Copyright © 2017 American Society for Hematology

Join the conversation